Annovis Bio Inc reports a Return on Equity (ROE) of -1,309.11%.

What is ANVS's dividend yield?

Annovis Bio Inc offers a dividend yield of 0.00%.

What is ANVS's Quality Score?

Our AI rates ANVS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ANVS?

Our AI Timing Score for ANVS is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ANVS belong to?

Annovis Bio Inc is classified under the Healthcare >> Biotechnology sector on the NYSE exchange

Annovis Bio Inc (ANVS) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

ANVS AI Analysis Summary

Our AI summary for ANVS: Annovis Bio Inc (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -1,309.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ANVS

Annovis Bio Inc

US:NYSE STOCK Healthcare >> Biotechnology News 98

USD 1.87

0.15 (8.72%) Day Change

Watchlist Portfolio Compare Chart

4.20

D/E

-1,309.1%

ROE

-251.9%

ROA

0.00%

Div Yield

ANNOVIS BIO INC
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 1.87 Price 0.15 (8.72%) Day Change	NEWS SCORE: 98

ANVS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.87
PBV / Sector	23.41 / 44,022.72
Earning Per Share	-1.05

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	1.31 M GREAT
Average 1W Daily Value	0.90 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-251.93 / 185,260.96
ROA Average (%) / Sector	-237.15 / 36,684.70
ROA Change Average (%) / Sector	170.59 / 422,221.66 GREAT
ROE (%) / Sector	-1,309.11 / 243,762.23
ROE Average (%) / Sector	-221.64 / 48,758.47
ROE Change Average (%) / Sector	-105.96 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 07:59:49
Symbol	ANVS
Name	ANNOVIS BIO INC
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	42.54 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	73.17 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355

Phone: 484 875 3192

Website: https://www.annovisbio.com

Sector: Healthcare >> Biotechnology

Description: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.